In a move to make healthcare more accessible, the Department of Health and Social Care (DHSC) has announced plans to empower pharmacy technicians, dental
therapists, and hygienists with enhanced authority following two public consultations run by the government in 2023.
Revealed by Primary Care Minister Andrea Leadsom on Thursday 28th March, this strategic decision promises to usher in "a faster, simpler, and fairer access to
primary care" by granting pharmacy professionals "the ability to both supply and administer medications".
Based on the public consultations that garnered widespread support, with 97% backing the empowerment of dental hygienists and therapists and 84% favouring similar
rights for pharmacy technicians, the new reform is aimed to cut through bureaucratic red tape and bolster efficiency in patient care.
Dental hygienists and therapists, under the proposed change, will be empowered to administer select medications, including pain relief and fluoride, without the
need for dentist approval.
Boots and the Pharmacists' Defence Association (PDA) Union have released a joint statement to confirm that there will be a pay increase for trainee
pharmacists in England and Northern Ireland from April 2024.
From 1 April 2024, the new hourly pay rate for trainee pharmacists working at Boots pharmacies will be £12.69 for Zone A in England/Northern Ireland, £13.79
for Zone B in England and £14.05 for Zone C in England.
"This increase will be applied centrally in the April pay run," said the statement from the Boots and the PDA Union.
Team members can see the new rate of pay in the Benefits Box during the annual enrolment window from 20 February 2024, it added.
In August 2023, pay for trainee pharmacists at Boots in England and Northern Ireland was increased to £11.64 per hour for Zone A, £12.77 per hour for Zone B
and £12.88 per hour for Zone C.
NHS England has agreed to offer an additional payment of £2.50 per jab if pharmacies would be willing to extend the duration of their COVID-19 vaccination
contract until 31st August 2024.
Pharmacies currently providing the autumn vaccination are asked to let their local commissioner know, by 22nd February 2024, if they can provide cover for a
potential Spring booster programme, if the Joint Committee on Vaccination and Immunisation (JCVI) advises in their guidance expected to be published soon.
NHS figures showed that more than 3,500 community pharmacies signed the contract to deliver COVID-19 vaccinations between 1 September 2023 and 31 March 2024, as
part of the autumn booster programme.
The health service is hoping that most of these pharmacies will be able to continue to support the Spring campaign, which will run from 1 April 2024 to 31st
August 2024, to help protect the nation's most vulnerable populations.
For the Spring campaign only, pharmacies would be offered an extra £2.50 per jab in addition to the existing item of service fee of £7.54, NHS England said.
Parents are advised to check their children's hair often as cases of head lice infestations are increasing in the UK amid rising temperatures.
Superdrug has reported a significant 121 per cent surge in sales of its head lice treatment spray, according to Wales Online.
The high-street chemist explains that head lice are particularly prevalent during this time of year as the warmer weather triggers infestations.
Head lice and nits (head lice eggs) are very common in young children and are picked up by head-to-head contact. The pesky insects make your head feel itchy.
The National Health Service (NHS) recommends taking immediate action against head lice as soon as they are detected. It is not necessary to see a GP for head
lice treatment.
Ensuring comprehensive healthcare services for the community necessitates collaboration between pharmacies and GP surgeries. However, several pharmacists
have voiced concerns about a lack of cooperation from their local GPs in implementing the Pharmacy First (PF) service.
In a survey conducted by the National Pharmacy Association (NPA) covering 470 pharmacies across England, three-quarters of pharmacists (77 per cent) indicated
that local GP practices are not appropriately referring patients to the new service.
The survey highlighted instances of patients either not being referred or being referred but found ineligible for support through Pharmacy First. Additionally,
one in five NPA members (19 per cent) felt that their local GP practices were not engaging with the initiative at all.
Commenting on the issue, NPA chair Nick Kaye said: "Feedback from across our network suggests that the rollout of Pharmacy First varies considerably from area
to area.